

Amendments to the Substitute Specification:

Replace the paragraph beginning at line 8 on page 18 with the following amended paragraph:

Fig. 3 (A,B) shows schematically the deduced amino acid sequence (A) (SEQ ID NO:1) of the B1 protein of the present invention and the determined nucleotide sequence coding therefor (B) (SEQ ID NO:2), wherein in the amino acid sequence is shown the kinase domain of B1 (boxed region at N-terminal end) and the CARD domain of B1 (underlined region at C-terminal end).

Replace the paragraph beginning at line 1 on page 57 with the following amended paragraph:

Cell death assay was carried out by growing 293-T cells in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% fetal calf serum, non-essential amino acids, 100 U/ml penicillin and 100 µg/ml streptomycin. 293-T cells (5×10^5 cells in 6 cm dishes) were transiently transfected using the calcium phosphate precipitation method with the cDNAs of the different constructs together with the β-galactosidase expression vector. In the experiments, the results of which are shown in ~~Table VI below~~ Figure 5, each dish was transfected with 1 µg of a p55 TNF-R, RIP or TRADD construct, 1 µg of the respective B1 or B1 mutant construct (or, as control, an empty vector), and 1 µg of pSV-β-gal

Appln. No. 09/445,223

Amdt. dated May 14, 2004

Supplemental Reply to Office action of January 15, 2004

(Promega). The extent of cell death at the end of the incubation period was assessed by determination of β -galactosidase expression, as described by Boldin et al., 1996.